ALX ONCOLOGY HOLDINGS INC - Common Stock, par value $0.001 per share (ALXO)
CUSIP: 00166B105
Q3 2024 13F Holders as of 30 Sep 2024
- Type / Class
- Equity / Common Stock, par value $0.001 per share
- Shares outstanding
- 132,496,020
- Total 13F shares
- 45,458,855
- Share change
- -3,004,944
- Total reported value
- $83,126,108
- Put/Call ratio
- 13%
- Price per share
- $1.82
- Number of holders
- 90
- Value change
- -$40,248,836
- Number of buys
- 56
- Number of sells
- 54
Quarterly Holders Quick Answers
What is CUSIP 00166B105?
CUSIP 00166B105 identifies ALXO - ALX ONCOLOGY HOLDINGS INC - Common Stock, par value $0.001 per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Related Filing Research
- Latest 13F filings for newly reported positions.
- Latest Schedule 13D/13G reports for ownership changes outside 13F cadence.
- Latest 10-Q/10-K reports for financial context tied to this issuer.
- Recent insider transactions for executive and insider activity.
- SEC investors directory and top value investors for manager drilldown.
- Back to full security ownership history.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 00166B105:
Top shareholders of ALXO - ALX ONCOLOGY HOLDINGS INC - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| LSV Associates, LLC |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
4,526,963
|
$61,575,751 | — | 13 Dec 2021 | |
| venBio Partners LLC |
13F
|
Company |
7.3%
|
9,699,925
|
$58,490,548 | — | 30 Jun 2024 | |
| FMR LLC |
13F
|
Company |
5.9%
|
7,814,996
|
$47,124,426 | — | 30 Jun 2024 | |
| Vivo Capital, LLC |
13F
|
Company |
3.2%
|
4,220,048
|
$25,446,889 | — | 30 Jun 2024 | |
| Redmile Group, LLC |
13F
|
Company |
3%
|
4,036,451
|
$24,339,800 | — | 30 Jun 2024 | |
| Vestal Point Capital, LP |
13F
|
Company |
2.7%
|
3,600,000
|
$21,708,000 | — | 30 Jun 2024 | |
| BlackRock Finance, Inc. |
13F
|
Company |
2%
|
2,687,619
|
$16,206,343 | — | 30 Jun 2024 | |
| MPM BioImpact LLC |
13F
|
Company |
1.6%
|
2,180,864
|
$13,150,610 | — | 30 Jun 2024 | |
| ORBIMED ADVISORS LLC |
13F
|
Company |
1.4%
|
1,894,462
|
$11,423,606 | — | 30 Jun 2024 | |
| VANGUARD GROUP INC |
13F
|
Company |
1.3%
|
1,727,248
|
$10,415,306 | — | 30 Jun 2024 | |
| Paradigm Biocapital Advisors LP |
13F
|
Company |
1.2%
|
1,575,605
|
$9,500,898 | — | 30 Jun 2024 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
1%
|
1,325,196
|
$7,990,932 | — | 30 Jun 2024 | |
| STATE STREET CORP |
13F
|
Company |
0.53%
|
705,547
|
$4,254,448 | — | 30 Jun 2024 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.53%
|
700,406
|
$4,224,247 | — | 30 Jun 2024 | |
| MORGAN STANLEY |
13F
|
Company |
0.51%
|
673,358
|
$4,060,355 | — | 30 Jun 2024 | |
| MARSHALL WACE, LLP |
13F
|
Company |
0.48%
|
635,679
|
$3,833,144 | — | 30 Jun 2024 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.33%
|
438,200
|
$2,642,346 | — | 30 Jun 2024 | |
| Privium Fund Management B.V. |
13F
|
Company |
0.3%
|
396,966
|
$2,270,646 | — | 30 Jun 2024 | |
| KENNEDY CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.23%
|
307,529
|
$1,854,400 | — | 30 Jun 2024 | |
| Point72 Asset Management, L.P. |
13F
|
Company |
0.23%
|
304,100
|
$1,833,725 | — | 30 Jun 2024 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
0.22%
|
292,226
|
$1,762,123 | — | 30 Jun 2024 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.18%
|
244,551
|
$1,474,643 | — | 30 Jun 2024 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.18%
|
236,020
|
$1,423,201 | — | 30 Jun 2024 | |
| JACOBS LEVY EQUITY MANAGEMENT, INC |
13F
|
Company |
0.18%
|
232,022
|
$1,399,093 | — | 30 Jun 2024 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.16%
|
215,252
|
$1,297,970 | — | 30 Jun 2024 | |
| Cubist Systematic Strategies, LLC |
13F
|
Company |
0.15%
|
199,441
|
$1,202,629 | — | 30 Jun 2024 | |
| WELLINGTON MANAGEMENT GROUP LLP |
13F
|
Company |
0.11%
|
145,717
|
$878,674 | — | 30 Jun 2024 | |
| Jump Financial, LLC |
13F
|
Company |
0.11%
|
140,000
|
$844,200 | — | 30 Jun 2024 | |
| Sophia Randolph |
3/4/5
|
CHIEF MEDICAL OFFICER |
—
mixed-class rows
|
420,711
mixed-class rows
|
$840,334 | — | 14 Aug 2024 | |
| Walleye Capital LLC |
13F
|
Company |
0.08%
|
109,762
|
$661,865 | — | 30 Jun 2024 | |
| Nuveen Asset Management, LLC |
13F
|
Company |
0.08%
|
105,894
|
$638,541 | — | 30 Jun 2024 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.08%
|
104,966
|
$632,945 | — | 30 Jun 2024 | |
| JANE STREET GROUP, LLC |
13F
|
Company |
0.06%
|
78,100
|
$470,943 | — | 30 Jun 2024 | |
| Deutsche Girozentrale DekaBank |
13F
|
Individual |
0.03%
|
41,000
|
$468,000 | — | 30 Jun 2024 | |
| STATE OF WISCONSIN INVESTMENT BOARD |
13F
|
Company |
0.06%
|
75,120
|
$452,974 | — | 30 Jun 2024 | |
| Susquehanna Portfolio Strategies, LLC |
13F
|
Company |
0.06%
|
73,468
|
$443,012 | — | 30 Jun 2024 | |
| ALLIANCEBERNSTEIN L.P. |
13F
|
Company |
0.05%
|
71,730
|
$432,532 | — | 30 Jun 2024 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
0.05%
|
68,511
|
$413,121 | — | 30 Jun 2024 | |
| TWO SIGMA ADVISERS, LP |
13F
|
Company |
0.05%
|
67,600
|
$407,628 | — | 30 Jun 2024 | |
| Aberdeen Group plc |
13F
|
Company |
0.05%
|
66,211
|
$399,252 | — | 30 Jun 2024 | |
| Inspire Investing, LLC |
13F
|
Company |
0.04%
|
58,707
|
$354,003 | — | 30 Jun 2024 | |
| RHUMBLINE ADVISERS |
13F
|
Company |
0.04%
|
55,220
|
$332,965 | — | 30 Jun 2024 | |
| Peter S. Garcia |
3/4/5
|
CHIEF FINANCIAL OFFICER |
—
mixed-class rows
|
201,516
mixed-class rows
|
$313,511 | — | 14 Aug 2024 | |
| Swiss National Bank |
13F
|
Company |
0.04%
|
49,400
|
$297,882 | — | 30 Jun 2024 | |
| BALYASNY ASSET MANAGEMENT L.P. |
13F
|
Company |
0.03%
|
44,149
|
$266,218 | — | 30 Jun 2024 | |
| Nan Fung Group Holdings Ltd |
13F
|
Company |
0.03%
|
41,950
|
$252,959 | — | 30 Jun 2024 | |
| ALGERT GLOBAL LLC |
13F
|
Company |
0.03%
|
41,215
|
$249,000 | — | 30 Jun 2024 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.03%
|
41,010
|
$247,290 | — | 30 Jun 2024 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0.03%
|
40,425
|
$243,763 | — | 30 Jun 2024 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
0.03%
|
34,543
|
$207,916 | — | 30 Jun 2024 |
Institutional Holders of ALX ONCOLOGY HOLDINGS INC - Common Stock, par value $0.001 per share (ALXO) as of Q3 2024
As of 30 Sep 2024,
ALX ONCOLOGY HOLDINGS INC - Common Stock, par value $0.001 per share (ALXO) was held by
90 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
45,458,855 shares.
The largest 10 holders included
venBio Partners LLC, FMR LLC, TANG CAPITAL MANAGEMENT LLC, Vivo Capital, LLC, Redmile Group, LLC, BlackRock, Inc., MPM BIOIMPACT LLC, MILLENNIUM MANAGEMENT LLC, VANGUARD GROUP INC, and GEODE CAPITAL MANAGEMENT, LLC.
This page lists
90
institutional shareholders reporting positions in this security
for the Q3 2024 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q3 2024 vs Q2 2024 Across Filers
Q2 2024 holders
107
Q3 2024 holders
90
Holder diff
-17
| Investor | Q2 2024 Shares | Q3 2024 Shares | Share Diff | Share Chg % | Q2 2024 Value $ | Q3 2024 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.